Company Overview
Snapshot
Founded in February 2022 by Guy Neev, Baccine operates with 1–10 employees. The company has secured funding across two rounds, with Terra Venture Partners leading a round in October 2025.
Business overview
Baccine is a pre-clinical biotechnology company focused on developing innovative bacteria-based cancer vaccines. The company's core technology utilizes a multi-acting approach to provide efficient immunotherapy treatments designed to increase response rates and reduce side effects through localized action. Baccine targets the healthcare and life sciences sectors, specifically patients, pharmaceuticals, and biotechnology, aiming to offer new hope for cancer patients.
Log in to access full profile ›Company Intelligence Q&A
- What is Baccine's primary focus?
- Baccine is a pre-clinical biotechnology company developing proprietary bacteria-based cancer vaccines for immunotherapy treatments.
- When was Baccine founded?
- Baccine was founded in February 2022.
- Who is a co-founder of Baccine?
- Guy Neev is a co-founder and CEO of Baccine.
- Which institution was involved in Baccine's establishment?
- Baccine was established in collaboration with the Weizmann Institute of Science, leveraging research on cancer resistance mechanisms and the tumor microenvironment.